Diffusion pharmaceuticals Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

About Diffusion pharmaceuticals Contact Number

Potential Treatment for. Hypoxia-related Indications. Diffusion Pharmaceuticals is actively evaluating the clinical effects of TSC on oxygenation and hypoxia-related indications, building upon data from prior clinical studies in peripheral artery disease, glioblastoma multiform (GBM) brain cancer, stroke, and COVID-19. Learn more.

Contact US: https://www.diffusionpharma.com/

Enhance

67 People Used

See More ››

Diffusion Pharmaceuticals

Contact Email [email protected]; Phone Number 4342200722; Diffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. Diffusion’s lead product candidate, TSC, is being developed to enhance the diffusion of

View Contact ››

Oxygen

47 People Used

See More ››

Our Company – Diffusion Pharmaceuticals Inc.

Contact Us; About Us. Diffusion Pharmaceuticals is developing a new kind of treatment for hypoxia, a potentially fatal shortage of oxygen in tissue. Oxygen is fuel for life. The constant uptake and delivery of oxygen within our body is necessary to sustain life whether at rest or under stress, in …

View Contact ››

Insights

127 People Used

See More ››

Diffusion Pharmaceuticals Inc. Company Profile

Find company research, competitor information, contact details & financial data for Diffusion Pharmaceuticals Inc. of Charlottesville, VA. Get the latest business insights from Dun & Bradstreet.

View Contact ››

Central

47 People Used

See More ››

Contact Us Diffusion Group

47 Central Avenue, West Molesey, Surrey, KT8 2QZ, United Kingdom. +44 (0) 20 8783 0033. diffusion@diffusion-group.com.

View Contact ››

Street

100 People Used

See More ››

SEC FORM D

Diffusion Pharmaceuticals Inc. Street Address 1 Street Address 2; 1317 CARLTON AVENUE: SUITE 200: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CHARLOTTESVILLE: VIRGINIA: 22902 (434) 220-0718

View Contact ››

Street

101 People Used

See More ››

SEC FORM D

DIFFUSION PHARMACEUTICALS LLC: Street Address 1 Street Address 2; 2020 AVON COURT, #4: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CHARLOTTESVILLE: VIRGINIA: 22902: 434-220-0718

View Contact ››

Diffusion

51 People Used

See More ››

Technology – Diffusion Pharmaceuticals Inc.

Technology – Diffusion Pharmaceuticals Inc. Oxygen is essential to life. Without it, our cells cannot burn glucose and lipids, which enable them to function properly. Without oxygen, we die. YouTube. Diffusion Pharmaceuticals. 56 subscribers. Subscribe. Diffusion Pharmaceuticals TSC MOA.

View Contact ››

Street

103 People Used

See More ››

FORM D

Diffusion Pharmaceuticals Inc. Street Address 1 Street Address 2; 2020 AVON COURT: SUITE 4: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CHARLOTTESVILLE: VIRGINIA: 22902 (434) 220-0718

View Contact ››

Diffusion

61 People Used

See More ››

Board of Directors – Diffusion Pharmaceuticals Inc.

Co-Founder and Chairman. David Kalergis is the co-founder of Diffusion Pharmaceuticals Inc. and served as the company’s Chief Executive Officer from 2004 until September 2020. Under his leadership, Diffusion grew into a publicly-traded clinical-stage drug development company commercializing a novel proprietary pharmaceutical technology.

View Contact ››

Business

55 People Used

See More ››

Diffusion Pharmaceuticals Inc. (DFFN) Company Profile

See the company profile for Diffusion Pharmaceuticals Inc. (DFFN) including business summary, industry/sector information, number of employees, business summary, corporate governance, key

View Contact ››

Diffusion

73 People Used

See More ››

Diffusion Pharmaceuticals

Diffusion Pharmaceuticals is a clinical stage company focused on improving the effectiveness of standard-of-care therapies for life-threatening treatment-resistant solid cancerous tumors, without adding harmful side effects.

View Contact ››

Medical/development

44 People Used

See More ››

About Us Lipidio Pharma

Menu Home About Focus Pipeline News Contact. (currently Diffusion Pharmaceuticals) from August 2011 until January 2015. Dr. Kolterman has served as a medical/development consultant to a number of biotechnology companies and currently is the Chief …

View Contact ››

Company

60 People Used

See More ››

Diffusion Pharmaceuticals (DFFN) Company Profile

Company profile for Diffusion Pharmaceuticals, including a description, list of executives, contact details and other key facts. Company profile for Diffusion Pharmaceuticals, including a description, list of executives, contact details and other key facts. CUSIP Number: 001053691: ISIN Number: US2537483057: Employer ID: 30-0645032: Company

View Contact ››

Diffusion

107 People Used

See More ››

Diffusion Pharmaceuticals Inc. :: Acorn Management

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on improving patient outcomes in unmet medical needs using its novel small molecule trans sodium crocetinate (TSC). Diffusion is developing TSC for use in conditions where hypoxia (oxygen deprivation) is known to diminish the effectiveness of standard of care (SOC

View Contact ››

Carlton

58 People Used

See More ››

Investors – Diffusion Pharmaceuticals Inc.

1317 Carlton Ave, Suite 200 Charlottesville, VA 22902. Cookie Policy. Privacy Policy

View Contact ››

Business

83 People Used

See More ››

DIFFUSION PHARMACEUTICALS

Diffusion Pharmaceuticals. Unclaimed. Edit. Write a Review. Add Photo. Share. Save. COVID-19 Updates. Edit. Contact the business for more information about recent service changes. Is this your business? Claim your business to immediately update business information, track page views, and more! Phone number (434) 220-0718. Get Directions

View Contact ››

Listing

207 People Used

See More ››

DIFFUSION PHARMACEUTICALS INC. : Notice of Delisting or

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2021, Diffusion Pharmaceuticals Inc. (the "Company") received a written notice from the staff (the "Staff") of the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a

View Contact ››

Stock

65 People Used

See More ››

Diffusion Pharmaceuticals Inc. (DFFN) Stock Forum

Find the latest Diffusion Pharmaceuticals Inc. (DFFN) stock discussion in Yahoo Finance''s forum. Share your opinion and gain insight from other stock traders and investors.

View Contact ››

Diffusion

75 People Used

See More ››

Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) is a publicly traded biotechnology and drug development company based in Charlottesville, Virginia, U.S. It was co-founded in 2001 by American life sciences entrepreneur David Kalergis and University of Virginia Chemical Engineering Professor John L. Gainer. Gainer is the inventor of the company’s platform technology of oxygen diffusion-enhancing

View Contact ››

Diffusion

107 People Used

See More ››

DIFFUSION PHARMACEUTICALS INC. : Shareholders Board

Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. Number of employees: 12 people. Managers: Name: Age: Since: Title: Robert J. Cobuzzi, Dr. 55: Company contact information: Diffusion Pharmaceuticals

View Contact ››

Please leave your comments here:

Popular Brands

Denso
Dbs
Daikin
Dow
Dsv
Dsm